Experimental DNA vaccine aims to train immune system against prostate cancer
NCT ID NCT07090148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether an experimental DNA vaccine (pTVG-HP) combined with the immunotherapy drug nivolumab and targeted radiation can help the immune system attack prostate cancer that has returned in a few spots. The study involves 14 men whose cancer has come back after prostate removal but who still have normal testosterone levels. The main goals are to see if the treatment can lower PSA levels and to check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-CASTRATE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
University of Wisconsin - Madison
RECRUITINGMadison, Wisconsin, 53705, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single radiation type spare prostate cancer patients from extra side effects?
- Can a Triple-Drug cocktail before surgery curb prostate Cancer's return?
- AI chatbot aims to demystify prostate cancer radiation — a trial puts it to the test
- New PET scan technique could map hidden prostate cancer recurrences
- Immune-Boosting drug and vaccine aim to fight returning prostate cancer
- Exercise may counteract side effects of prostate cancer hormone therapy